BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Malignant Hyperthermia

Below is an extended Malignant Hyperthermia research listing. Click here to return to the Malignant Hyperthermia main in depth entry.

Recent Publications on Malignant Hyperthermia:

Reply to 'Malignant hyperthermia must not be excluded due to uneventful previous anaesthesias'
Two patients with solid tumors were treated with 21-day continuous...
Direct Link
16th August, 2008
Uneventful anaesthesia does not exclude malignant hyperthermia.
Two patients with solid tumors were treated with 21-day continuous...
Direct Link
16th August, 2008
Mirror, mirror on the wall.
Two patients with solid tumors were treated with 21-day continuous...
Direct Link
14th August, 2008
Channels active in the excitability of nerves and skeletal muscles across the neuromuscular junction: basic function and pathophysiology.
Ion channels are essential for the basic physiological function of...
Direct Link
7th August, 2008
Division of Basic Biomedical Sciences, Sanford School of Medicine,
A patient with severe central core disease.
The skeletal muscle Ca(2+) release channel (RyR1), a homotetramer,...
Direct Link
5th August, 2008
Be prepared: malignant hyperthermia. 29th July, 2008
Subnanometer-resolution electron cryomicroscopy-based domain models for the cytoplasmic region of skeletal muscle RyR channel.
The skeletal muscle Ca(2+) release channel (RyR1), a homotetramer,...
Direct Link
16th July, 2008
National Center for Macromolecular Imaging, Verna and Marrs McLean
Malignant hyperthermia or malignant hyperthermia-like syndrome.
The skeletal muscle Ca(2+) release channel (RyR1), a homotetramer,...
Direct Link
12th July, 2008
Nonmalignant hyperthermia and malignant hyperthermia confused.
The skeletal muscle Ca(2+) release channel (RyR1), a homotetramer,...
Direct Link
12th July, 2008
Successful management of malignant hyperthermia during orthognathic surgery: a case report.
The skeletal muscle Ca(2+) release channel (RyR1), a homotetramer,...
Direct Link
8th July, 2008
School of Dentistry of Pernambuco, and Oswaldo Cruz Hospital, University
Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. 21st June, 2008
Department of Anaesthesia and Pain Management, Royal Melbourne Hospital,
DNA analysis and malignant hyperthermia susceptibility. 21st June, 2008
[In-vivo diagnosis of malignant hyperthermia susceptibility : A microdialysis study.]
BACKGROUND: In malignant hyperthermia (MH), volatile anesthetics induce...
Direct Link
20th June, 2008
Klinik und Poliklinik fur Anasthesiologie, Zentrum fur Operative Medizin,
Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia.
Native American myopathy (NAM) [OMIM 255995], a putative autosomal...
Direct Link
17th June, 2008
Curriculum in Genetics and Molecular Biology, University of North
Reduced threshold for luminal Ca2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia.
Naturally occurring mutations in the skeletal muscle Ca(2+) release...
Direct Link
29th May, 2008
Libin Cardiovascular Institutes of Alberta, Department of Physiology,
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional